{
  "attach_pages": "8",
  "attach_size": "928",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201702210354796437_1.pdf?1487668622000.pdf",
  "company_code": "80114781",
  "eitime": "2017-02-21 09:17:17",
  "extend": {},
  "info_code": "AP201702210354796437",
  "language": "0",
  "notice_date": "2017-02-21 00:00:00",
  "notice_title": "事件点评：多西他赛ANDA获批，2017年或成恒瑞海外ANDA+收入双爆发年",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "publish_relation": {
    "originalCode": "465",
    "publishName": "化学制药"
  },
  "rating": "A",
  "researcher": "张金洋",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "恒瑞医药",
      "short_name_ch": "恒瑞医药",
      "short_name_cht": "恒瑞醫藥",
      "short_name_en": "HENGRUI PHARMA",
      "stock": "600276"
    }
  ],
  "short_name": "恒瑞医药",
  "source_sample_name": "东兴证券",
  "star": "1"
}